Delivery Order SPE2DR25D3004-SPE2DR26FXUJ4
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,477.61 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 150 ml quantity. The contract is a firm fixed-price delivery order with no set-aside designation, indicating competitive award, and is scheduled for completion by August 26, 2025. The product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $2,475.27 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity. The contract is a firm fixed-price delivery order with no set-aside designation, awarded on January 7, 2026, with an ultimate completion date of January 8, 2026. Performance will be executed from the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 17, 2025, for the supply of Quillivant XR 25 mg/5 mL suspension in 150 mL quantities, with a contract ceiling value of $2,802.86. This is a firm fixed-price delivery order with an ultimate completion date of November 18, 2025, with no set-aside designation applied. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania—the location of performance for this contract—is a major pharmaceutical...
- The Defense Logistics Agency awarded a $1,218.48 firm fixed-price delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 180 ml quantities, with performance completion scheduled for November 4, 2025. This non-set-aside award was competitively procured and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $2,751.84 delivery order to AmerisourceBergen Drug Corp on January 12, 2026, for Quillivant XR 25 mg/5 ml suspension in 150 ml quantities, with delivery expected by January 13, 2026. This non-set-aside, firm fixed-price order was competitively awarded and will be performed at the contractor's Conshohocken, Pennsylvania facility. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc. (doing business as AmerisourceBergen), is a major...
- The Defense Logistics Agency awarded a $1,054.32 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (120 ml), with an ultimate completion date of November 28, 2025. This competitively awarded, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor,...
- The Defense Logistics Agency awarded a $1,654.12 delivery order to AmerisourceBergen Drug Corp on January 5, 2026, for the supply of Quillivant XR 25 mg/5 ml suspension (120 ml). This firm fixed-price delivery order, with completion targeted for January 6, 2026, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The contract was competitively awarded with no...
- The Defense Logistics Agency awarded a $1,030.10 delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (180 ml), with an ultimate completion date of December 11, 2025. This is a firm fixed-price, non-set-aside contract utilizing a competitive award process. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal healthcare vendor that supplies a comprehensive portfolio of medications and medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,164.94 to supply Quillivant XR 25 mg/5 ml suspension in a 60 ml quantity, with an ultimate completion date of November 4, 2025. This competitively awarded, firm fixed-price delivery order was issued on November 3, 2025, with no set-aside designation. The place of performance is located at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is executed under...
- The Defense Logistics Agency awarded a delivery order valued at $4,361.39 to AmerisourceBergen Drug Corp on November 24, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities, with an ultimate completion date of November 25, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under open competition. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- SPE2DR25D3004Indefinite Delivery Contract
- SPE2DR25D3004-SPE2DR26FXUJ4Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,662.52 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension in 120ml quantities. The contract is a firm fixed-price delivery order with no set-aside designation, issued on January 16, 2026, with an ultimate completion date of January 20, 2026. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is the awardee on this child contract under its parent organization Cencora, Inc. (doing business as AmerisourceBergen). This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, and medical supplies across multiple therapeutic domains. The pharmaceutical product being delivered under this order—Quillivant XR, a treatment for attention deficit hyperactivity disorder—supports the Defense Health Agency and military medical treatment facilities' medication supply chain requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 1/15/26 |